These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 24334974)

  • 1. Atazanavir-induced urine crystals demonstrated by infrared spectroscopic analysis.
    Inagaki I; Adachi M; Ito H; Yasuda M; Tsurumi H; Deguchi T; Seishima M
    Urol Int; 2015; 94(1):121-4. PubMed ID: 24334974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urolithiasis in HIV-positive patients treated with atazanavir.
    Couzigou C; Daudon M; Meynard JL; Borsa-Lebas F; Higueret D; Escaut L; Zucman D; Liotier JY; Quencez JL; Asselah K; May T; Neau D; Vittecoq D
    Clin Infect Dis; 2007 Oct; 45(8):e105-8. PubMed ID: 17879904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atazanavir: urolithiasis.
    Prescrire Int; 2014 Sep; 23(152):214. PubMed ID: 25325124
    [No Abstract]   [Full Text] [Related]  

  • 4. High levels of atazanavir and darunavir in urine and crystalluria in asymptomatic patients.
    de Lastours V; Ferrari Rafael De Silva E; Daudon M; Porcher R; Loze B; Sauvageon H; Molina JM
    J Antimicrob Chemother; 2013 Aug; 68(8):1850-6. PubMed ID: 23599359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atazanavir urolithiasis.
    Chang HR; Pella PM
    N Engl J Med; 2006 Nov; 355(20):2158-9. PubMed ID: 17108352
    [No Abstract]   [Full Text] [Related]  

  • 6. Chronic interstitial nephritis in an HIV type-1-infected patient receiving ritonavir-boosted atazanavir.
    Viglietti D; Verine J; De Castro N; Scemla A; Daudon M; Glotz D; Pillebout E
    Antivir Ther; 2011; 16(1):119-21. PubMed ID: 21311116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urolithiasis associated with atazanavir may mask a metabolic 'channelling' bias.
    Guaraldi G; Dolci G; Bellasi A
    J Antimicrob Chemother; 2014 Jan; 69(1):284-5. PubMed ID: 23934771
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
    Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E;
    Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical features and risk factors for atazanavir (ATV)-associated urolithiasis: a case-control study.
    Lafaurie M; De Sousa B; Ponscarme D; Lapidus N; Daudon M; Weiss L; Rioux C; Fourn E; Katlama C; Molina JM
    PLoS One; 2014; 9(11):e112836. PubMed ID: 25409506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
    Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Adverse effects of atazanavir].
    Palacios R; González M; Ruiz J; Santos J
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():41-4. PubMed ID: 20116616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does atazanavir cause lipodystrophy?
    Gazzard BG; Moyle G
    J HIV Ther; 2004 May; 9(2):41-4. PubMed ID: 15238875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efavirenz urolithiasis.
    Izzedine H; Valantin MA; Daudon M; Mohand HA; Caby F; Katlama C
    AIDS; 2007 Sep; 21(14):1992. PubMed ID: 17721118
    [No Abstract]   [Full Text] [Related]  

  • 14. Atazanavir crystal nephropathy.
    Izzedine H; M'rad MB; Bardier A; Daudon M; Salmon D
    AIDS; 2007 Nov; 21(17):2357-8. PubMed ID: 18090291
    [No Abstract]   [Full Text] [Related]  

  • 15. High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy.
    Hamada Y; Nishijima T; Watanabe K; Komatsu H; Tsukada K; Teruya K; Gatanaga H; Kikuchi Y; Oka S
    Clin Infect Dis; 2012 Nov; 55(9):1262-9. PubMed ID: 22820542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study).
    Di Giambenedetto S; Fabbiani M; Colafigli M; Ciccarelli N; Farina S; Sidella L; D'Avino A; Mondi A; Cingolani A; Tamburrini E; Murri R; Navarra P; Cauda R; De Luca A
    J Antimicrob Chemother; 2013 Jun; 68(6):1364-72. PubMed ID: 23372058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of switch to atazanavir-containing combination antiretroviral therapy in HIV-1-infected patients with hyperlipidemia.
    Lu CL; Lin YH; Wong WW; Lin HH; Ho MW; Wang NC; Hsieh SM; Sheng WH; Hung CC; Chen MY
    J Microbiol Immunol Infect; 2011 Aug; 44(4):258-64. PubMed ID: 21524961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
    Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Thiry A; McGrath D;
    Lancet; 2008 Aug; 372(9639):646-55. PubMed ID: 18722869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atazanavir-associated choledocholithiasis leading to acute hepatitis in an HIV-infected adult.
    Jacques AC; Giguère P; Zhang G; Touchie C; la Porte CJ
    Ann Pharmacother; 2010 Jan; 44(1):202-6. PubMed ID: 19955297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atazanavir urinary stones in an HIV-infected patient.
    Pacanowski J; Poirier JM; Petit I; Meynard JL; Girard PM
    AIDS; 2006 Oct; 20(16):2131. PubMed ID: 17053366
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.